Progress in gene therapy for primary immunodeficiencies using lentiviral vectors.

Area of Science:

• Immunology
• Genetics
• Molecular Biology

Background:

• Primary immunodeficiencies (PIDs) are a group of rare genetic disorders affecting the immune system.
• Gene therapy offers a potential curative approach for PIDs by correcting the underlying genetic defect.
• Lentiviral vectors have emerged as a promising tool for gene delivery in gene therapy.

Purpose of the Study:

• To review the recent progress in lentiviral gene therapy for PIDs.
• To summarize the history and current state of lentiviral vector development.
• To discuss advancements in preclinical and clinical applications for specific PIDs.

Main Methods:

• Review of recent scientific literature on lentiviral gene therapy for PIDs.
• Analysis of preclinical studies and ongoing clinical trials.
• Discussion of lentiviral vector improvements and historical retroviral vector trials.

Main Results:

• Focus on lentiviral gene therapy for Wiskott-Aldrich syndrome, chronic granulomatous disease, ADA-SCID, and X-linked SCID.
• Demonstration of lentiviral gene therapy's effectiveness in preclinical models and clinical trials.
• Highlighting improvements in lentiviral vector platforms and their application.

Conclusions:

• Lentiviral gene therapy is an effective treatment for PIDs, offering potential long-term clinical benefits.
• Significant progress has been made in developing lentiviral gene therapy platforms for rare genetic diseases.
• Future advancements may involve in-vivo gene therapy and gene-repair platforms for certain PIDs.